Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2017

View Archived Issues

Identification of AAT-008, a potent and selective prostaglandin EP4 receptor antagonist

FDA awards orphan drug designation to Moleculin's liposomal annamycin for AML

RL-71 shows promise in suppressing tumor growth in triple-negative breast cancer mouse model

Pfizer initiates phase II study of PF-06741086 in severe hemophilia

EMA accepts for review brexpiprazole MAA for schizophrenia in adults

EMA grants orphan drug designation to NiCord in HSCT

BioLineRx acquires Agalimmune

Herantis gets Swedish clearance to begin phase I/II trial of CDNF in Parkinson's disease

Toxicity and pharmacokinetics of myocardial infarction candidate RUC-4 studied in vivo

Merck & Co. initiates phase IIa study of MK-8189 in schizophrenia

Janssen identifies novel cannabinoid receptor 1 inverse agonists

Pharmacokinetic and pharmacodynamic data presented from first clinical trial of BMS-962212

Santen Pharmaceutical patents glucocorticoid receptor agonists

Janssen Pharmaceutica synthesizes novel analgesic compounds

Bristol-Myers Squibb synthesizes novel myeloperoxidase and/or eosinophil peroxidase inhibitors

Ocean University of China describes new anti-HSV-1 compounds

ImmunoCellular Therapeutics and Memgen sign immuno-oncology collaboration letter of intent

NR4A1, a novel target for the treatment of alveolar rhabdomyosarcoma

FDA approves Bavencio for metastatic Merkel cell carcinoma

European Commission approves Amgen's adalimumab biosimilar Amgevita

Torii seeks to expand Japanese label for Miticure to include pediatric patients

FDA grants breakthrough therapy designation to Rituxan for pemphigus vulgaris

Merrimack initiates phase I study of MM-310 in solid tumors

FDA accepts for filing Solosec NDA for bacterial vaginosis

FDA approves Symproic for opioid-induced constipation in adults with chronic non-cancer pain

IDMC recommends continuation of phase II/III trial of NBTXR-3 in soft tissue sarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...